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Abstract 
Aim To investigate whether expression of an anti-CD4 antibody fragment (scFv) by a lentivector-
transduced donor cornea can prolong rat corneal allograft survival. Methods Inbred Fischer 344 rats 
received penetrating corneal allografts from Wistar-Furth donors after a 3h transduction of the 
donor cornea with a lentivector carrying anti-CD4scFv cDNA (Lv-CD4scFv), a lentivector carrying the 
reporter gene eYFP (LV-eYFP) or an adenoviral vector carrying anti-CD4 scFv cDNA (Ad-CD4scFv). 
Unmodified controls were also performed. Graft survival was assessed by corneal clarity and 
rejection was confirmed histologically. Results In organ-cultured corneas, expression of anti-CD4 
scFv was detected at 2 days post-transduction with the adenoviral vector, compared with 5 days 
post-transduction with the lentivector, and was 10-fold higher from the former. More inflammation 
was observed in Ad-CD4scFv-modified allografts than in Lv-CD4scFv-modified grafts at 15 days post-
surgery (p=0.01). The median time to rejection for unmodified, LV-eYFP and Ad-CD4scFv grafts was 
day 17, compared with day 22 for Lv-CD4scFv grafts (p≤0.018). Conclusion Donor corneas 
transduced with a lentiviral vector carrying anti-CD4scFv cDNA showed a modest but significant 
prolongation in graft survival compared with unmodified, Lv-eYFP and Ad-CD4scFv grafts. However, 
rejection still occurred in all Lv-CD4scFv grafts, indicating that sensitization may have been delayed 
but was not prevented. 
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Introduction 
Despite topical application of glucocorticosteroids, approximately 40% of corneal allografts fail after 
10 years, most commonly caused from irreversible immunological rejection mediated primarily by 
CD4+ T cells.1 Strategies that have greatly improved the outcomes for vascular organ transplants, 
such as human leucocyte antigen (HLA)-matching and systemic immunosuppression have shown 
limited success when applied to corneal transplantation.  
Monoclonal antibodies (mAb) have shown some promise as therapeutic drugs for corneal 
transplantation. In humans, systemic delivery of CAMPATH-1H (a humanised mAb against CD52), can 
reduce ocular inflammation in patients including those with corneal grafts.2 Furthermore, systemic 
delivery of anti-CD4 mAb can prolong corneal graft survival in mice3 4 and rats.5 6 Cytotoxic T 
lymphocyte antigen-4 (CTLA-4), a competitive inhibitor of CD28 signalling, binds with high affinity to 
CD80/CD86 co-stimulatory molecules expressed on antigen-presenting cells (APCs). Delivery of a 
soluble CTLA-4 construct or an anti-CD28 mAb can prolong corneal graft survival in mice,7-9 rats10 11 
and rabbits.12 In addition, systemic delivery of anti-CD40L mAb can prolong corneal allograft survival 
in mice.7  
With the exception of one study,13 the topical application of whole antibodies to the cornea has 
shown limited success at prolonging corneal allograft survival in animal models. This is most likely 
due to the structure of the cornea, which forms a barrier to many therapeutics, including whole 
antibodies.14  
Single chain fragment variables (scFv) consist of the variable heavy and the variable light regions 
from a whole antibody, connected using a linker peptide. ScFv can penetrate pig corneas in vitro, but 
are rapidly cleared from the eye.14 Gene transfer vectors can be used to produce sustained 
expression of a scFv within ocular tissue. The cornea is highly amenable to such a therapy as it is 
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feasible to transduce donor corneas ex vivo with a small dose of vector prior to transplantation in a 
single intervention. 
Anti-CD4 scFv has been shown previously to inhibit alloproliferation in a mixed lymphocyte reaction 
(MLR).15 However, despite robust expression of anti-CD4 scFv from rat corneas 4-5 days after 
transduction with an adenoviral vector carrying the cDNA for anti-CD4 scFv (Ad-CD4scFv) during in 
vitro culture, Ad-CD4scFv allografts rejected at the same tempo as unmodified allografts.15 
Adenovirus is known to be immunogenic and to produce only transient transgene expression and 
both of these factors may have contributed to the null effect of the Ad-CD4scFv therapy. 
The aims of this study were to determine whether sustained expression of anti-CD4 scFv by the rat 
cornea could be achieved after lentiviral transduction and whether this could modulate corneal 
allograft survival in a rat model of corneal transplantation. 
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Methods  
Approval was obtained from the institutional Animal Welfare Committee. Adult (12-week) male 
inbred Fischer 344 (F344, RTlvl) and Wistar-Furth (WF, RTlu) rats were bred within our facility. Rats 
were housed at 21°C in 50-55% humidity under a 12h light/12h dark cycle, and were allowed access 
ad libitum to water and dry rations (Ridley AgriProducts, Melbourne, Australia). The genetic integrity 
of inbred strains was maintained by lineage records and tested yearly by allozyme electrophoresis. 
 
Viral vector construction, titration and purification 
A replication-deficient E1-, E3-deleted serotype 5 adenovirus (Adv) encoding anti-CD4 scFv with a 
factor H secretory sequence (fHSS) and 6-histidine tag (6-his) under individual CMV promoter control 
(Ad-CD4scFv) was purified as previously described.15 This construct also encoded enhanced green 
fluorescence protein (eGFP) which was driven under a separate CMV promoter. Adv titre was 
determined by the tissue culture infectious dose method (TCID50) on HEK-293A cells and was 
expressed as plaque forming units (pfu)/ml. Adv-CD4scFv had a titre of 4 x 108 pfu/ml. 
 
Anti-CD4 scFv cDNA (with fHSS and 6-his) was amplified from the Ad-CD4scFv shuttle plasmid and 
cloned into pHIV1-SDmSV-DLTR within the same open reading frame as a 2A self-processing 
sequence (an 18 amino acid sequence which cleaves at its C-terminus through a ribosomal ‘skip’ 
mechanism, and allows expression of multiple transgenes within a single open reading frame) and 
enhanced yellow fluorescence protein (eYFP) cDNA to form the construct pHIV-1SDmSV-
CD4scFv_F2A_eYFP-DLTR, which was used to generate the lentiviral vector (Lv), Lv-CD4scFv. The 
pHIV-1SDmSV-eYFP-DLTR plasmid was used to generate the Lv, Lv-eYFP.16 Lv production was 
performed as described previously.16 All vector stocks were tested for replication-competent 
lentivirus by assaying expression of HIV-1 p24 (HIV-1 p24 ELISA kit, PerkinElmer Inc, Boston, MA, 
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USA) in transduced cells over 3 weeks and found to be negative. Lv titration was performed using 
methods modified from a previously described protocol.17 Lv titre was determined through proviral 
integration using quantitative real-time PCR (qPCR) on genomic DNA (gDNA) from transduced A549 
cells (CCL-185, American Type Culture Collection), after 4 weeks of culture. A gDNA standard made 
from A549 cells containing one copy of the Lv genome and two copies of the transferrin gene per cell 
was used for calibration. Primers were designed to detect the gag sequence, forward 
5’AGCTAGAACGATTTCGCAGTTGAT3’ and reverse ‘5 CCAGTATTTGTCTACAGCCTTCTGA3’ and the 
human transferrin sequence (reference gene), forward 5’GCCCTGCCTGCCTACA3’ and reverse 
5’CAGGTTGTGCTTCTGACTCACT3’. qPCR was performed using Quantitect™ SYBR Green PCR master 
mix (Qiagen, Hilden, Germany) in a Rotor-Gene™ 6000 real time thermal cycler (Corbett Life Science, 
Mortlake, NSW, Australia). Cycle threshold (Ct) values were determined using the Rotor-Gene™ 6000 
Series Software 1.7 (Corbett Life Science, Mortlake, NSW, Australia) and the ΔΔ-Ct method was used 
to calculate the copy number of gag per cell. Titres were expressed as transducing units/ml. The titre 
of Lv-eYFP was 2.38 x 109 TU/ml and the titre of Lv-CD4scFv was 1.25 x 109 TU/ml. 
 
In vitro transduction of rat corneas 
Globes were removed and decontaminated in 10% w/v povidone iodine (Faulding Pharmaceuticals, 
Salisbury, SA). Corneas were dissected and the iris detached. Corneas were placed in HEPES-buffered 
RPMI( Gibco GRL, Gaithersburg, MD, USA) containing 2% FCS, then transferred to a round-bottom 96 
well plate (Nunc, Roskilde, Denmark), endothelium up. HEPES-buffered RPMI (2% FCS) containing 
either Lv (2.5 x 107 TU/cornea; multiplicity of infection (MOI = 400)) or Adv (2 x 107 pfu/ml; MOI = 
320) was added dropwise to the cornea and incubated for 3 hours at 37°C, 5% CO2 in air. Corneas to 
be used for transplantation were washed twice in HEPES-buffered RPMI (without serum or L-
glutamine) and rinsed in ophthalmic BSS ≤ 10 min prior to surgery. Corneas that were used for 
culture were placed in 2ml HEPES-buffered RPMI (10% FCS) supplemented with 2.5 µg/ml 
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amphotericin B (Amphostat, Thermo Electron, Melbourne, Vic, Australia) in a 24 well plate and 
incubated for up to 11 days at 37°C, 5% CO2 in air, with a medium change every 48-72 h. 
 
Reporter gene expression from transduced corneas 
Detection of eYFP from transduced rat corneas was performed using methods described 
previously.16 
 
Detection of functional anti-CD4 scFv by flow cytometry  
Functional anti-CD4scFv was detected by flow cytometry on CD4-positive rat thymocytes as 
described previously.14  
 
Orthotopic corneal transplantation in the rat 
Recipient male F344 rats received penetrating 3 mm diameter corneal allografts from male WF 
donors under general anaesthesia, as described previously.18 The WF/F344 strain combination 
represents multiple major and minor histocompatibility barrier differences. Donor corneas were 
secured with eight interrupted 10-0 nylon sutures. Grafts were examined daily under the operating 
microscope and grafted eyes were scored separately for clarity, corneal neovascularisation and 
inflammation on a 0-4 numerical scale with 0.1 increments. Corneal graft clarity was used to 
determine graft failure. Grafts were deemed failures when clarity scores ≥2.0 (graft obscuring 
observation of iris vessels). After rejection or after 60 days, rats were euthanised by isoflurane 
overdose. Globes were removed and processed for histology. 
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Histology 
Tissue samples were fixed in buffered formalin for at least 24 h, dehydrated and embedded in 
paraffin wax. Sections (5 mm thick) were cut at the microtome and mounted on chrome alum-
subbed slides prior to staining with H&E and mounting in DePeX mounting medium (BDH Laboratory 
Supplies, Poole, UK). 
 
Statistical analyses 
Unpaired two-tailed Student t-tests were performed using Microsoft Office Excel 2003 (Microsoft 
Corporation, Redmond, WA, USA) to determine statistical differences for in vitro assays. Corneal 
graft survival was analysed by non-parametric statistical analysis using SPSS statistical software (SPSS 
Inc., Chicago, IL, USA). For comparisons amongst three or more groups, a Kruskal-Wallis test 
(corrected for ties and with Bonferroni correction where appropriate) was performed, and to further 
identify which groups were statistically different from one another, pair-wise Mann Whitney U-tests 
(corrected for ties) was used. For comparisons between two groups, Mann Whitney U-tests 
(corrected for ties) were performed. Significance was set at p<0.05. 
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Results 
Lv-eYFP-transduced rat corneas showed transduction of 49% of endothelial cells after a 3h 
transduction with Lv-eYFP (MOI=400). Transduced corneas showed minimal oedema after the 3h 
transduction and the mean corneal endothelial cell density of the Lv-eYFP-transduced corneas was 
comparable to unmodified corneas (1346 ± 189 cells/mm2 and 2103 ± 445 cells/mm2 respectively; 
n=3; p > 0.05). 
Next, we assessed expression of anti-CD4 scFv from rat corneas transduced with either Lv-CD4scFv 
(MOI=400) or Ad-CD4scFv (MOI=320) after a 3h transduction in vitro. Untransduced corneas were 
treated in the same manner as the transduced corneas, excluding addition of virus. After the 3h 
transduction, corneas were washed and cultured for 11 days. Secretion of functional anti-CD4 scFv 
into the culture supernatant was detected via the 6-his tag using flow cytometry on rat CD4+ 
thymocytes (Figure 1). 
Significantly higher levels of anti-CD4 scFv were detected in the culture supernatant of corneas 
transduced with Ad-CD4scFv, compared to the Lv-CD4scFv from days 2-11 (p<0.05), with a 10-fold 
difference seen at day 5 (Figure 1). However, even from the Lv-CD4scFv-transduced corneas, 33-37 
ng of scFv was secreted every 3 days. Anti-rat CD4 scFv expression was detected from 2 days after 
transduction in Ad-CD4scFv corneas, whilst Lv-CD4scFv corneas did not express detectable levels of 
anti-rat CD4 scFv until day 5 post transduction. Untransduced corneas produced no detectable 
expression of the anti-rat CD4 scFv (Figure 1).  
Next, corneal allografts were either left unmodified or transduced with Lv-CD4scFv, Lv-eYFP or Ad-
CD4scFv prior to transplantation (Table 1). All but one allograft underwent rejection. The median 
time to rejection for unmodified (n=10), Lv-eYFP (n=10) and Ad-CD4scFv (n=8) allografts was 17 days. 
Lv-CD4scFv allografts (n=8) experienced a modest, but significant, prolongation in survival compared 
with other allografts with a median day to rejection of 22 days. Immunological rejection of Lv-
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CD4scFv grafts was similar both clinically and histologically to unmodified and Lv-eYFP allografts and 
there was no difference in the day of vessel infiltration into the graft post-operatively. However, 
significantly more inflammation was observed in the Ad-CD4scFv-transduced allografts compared to 
the Lv-CD4scFv-transduced allografts at day 15 post-operatively (Table 2). 
Table 1: Corneal graft survival following ex vivo transduction of donor corneas with viral vectors.  
Treatment Graft N Median day of host 
vessel crossing into 
graft 
Day to rejection Median day 
to rejection 
Unmodified allograft 10 10 11, 12, 14, 15, 16, , 18, 19, 
19, 20, >60 
17 
Lv-eYFP allograft 10 10 10, 11, 14, 15, 16, 18, 19, 19, 
27, 30 
17 
Lv-CD4scFv allograft 8 10 17, 20, 20, 21, 22, 25, 27, 38 22* 
Ad-CD4scFv allograft 8 11 13, 13, 14, 16, 17, 18, 21, 22 17 
* p=0.004 compared with the unmodified and LV-eYFP allografts, (Kruskal-Wallis test, corrected for 
ties, with Bonferroni adjustment) and p=0.018 compared with Ad-CD4scFv (Mann Whitney U-test, 
corrected for ties). 
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Table 2: Ocular inflammation in corneal allografts after ex vivo transduction of the donor cornea 
with viral vectors prior to corneal transplantation. 
*p=0.01 compared with Lv-CD4scFv (Mann Whitney U-test, corrected for ties). 
 
 
Treatment  Median inflammation score 
 n Day 1 Day 5 Day 10 Day 15 
Unmodified 10 0.5 0.6 0.4 0.1 
Lv-eYFP 10 0.8 0.9 0.2 0.5 
Lv-CD4scFv 8 0.7 0.8 0.3 0.05 
Ad-CD4scFv 8 0.7 0.7 0.2 0.9* 
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Discussion 
Lv-CD4scFv allografts showed a modest but significant prolongation in survival compared with 
unmodified, Lv-eYFP or Ad-CD4scFv allografts. However, all Lv-CD4scFv allografts did undergo 
rejection, and the clinical and histological assessments of rejection were similar to the unmodified 
and Lv-eYFP allografts. As reported previously,15 Ad-CD4scFv-transduction of corneal allografts did 
not modulate the tempo of rejection.  
Why was the tempo of rejection modified after lentiviral but not adenoviral transduction? First, the 
immunogenicity of the Adv may have offset the immunosuppressive abilities of the anti-CD4 scFv, 
and prevented any modulation in allograft survival. Adenoviral vectors are well-established to be 
immunogenic in the eye.19 We noted significantly more inflammation in Ad-CD4scFv-treated 
allografts than in Lv-CD4scFv-treated allografts at 15 days post-graft. We surmise that the pro-
inflammatory nature of the adenoviral vector may have counteracted the potential 
immunomodulatory effects of anti-CD4 scFv secretion into the anterior chamber and limited 
transgene expression. Second, expression of the anti-CD4 scFv from the adenoviral vector may have 
been too transient.15 We have previously reported long-term expression of the reporter gene eYFP 
(>60 days post-graft) in rat corneal isografts after transfection of the donor cornea with the same 
lentiviral vector used herein.16 We hypothesize that the anti-CD4 scFv was expressed for a similar 
time, as its expression was driven by the same internal promoter (SV40) within the same lentivector. 
The eGFP reporter protein is detectable as early as one day after transduction of the rat cornea with 
an adenoviral vector analogous to the one used in this study,15 and two days after transduction with 
the lentiviral vector.16 In vivo, expression of eGFP is high at 1 and 3 days post-transduced with the 
adenoviral vector,15 compared with the lentivector, but is low by day 14 and virtually undetectable 
by day 30 (data not shown). Thus, compared with the lentivector, adenovirus-mediated gene 
transfer resulted in expression of greater amounts of transgenic protein, but for a shorter period of 
time and at the expense of more ocular inflammation. 
Archived at Flinders University: dspace.flinders.edu.au
13 
 
Corneal allografts expressing LV-CD4scFv exhibited a significant delay in their tempo of graft 
rejection, compared with controls, but all grafts were eventually rejected. The evidence described 
herein (and from previously-published work) supports the contention that in vitro, more scFv is 
produced from an adenovirus-transfected rat cornea than from a lentivirus-transduced cornea, and 
that the kinetics of expression may be a little faster in the former. We also have evidence to show 
that in vivo as distinct from in vitro, expression from the adenoviral vector is transient whereas 
expression from the lentiviral vector is more long-lasting. We found that 33-37 ng of scFv protein 
was secreted from a Lv-transduced rat cornea every 3 days. We have previously reported that 26 ng 
purified anti-CD4 scFv at a concentration of 0.13 ng/µl can inhibit proliferation in a MLR,15 however 
an insufficient amount of transgenic protein at the site of action in vivo is a possible reason for the 
delayed rejection response, rather than its abolition. 
It should be emphasized that the site at which sensitisation to ocular alloantigens occurs in rats is 
unclear. In the mouse, bilateral removal of the cervical lymph nodes induces indefinite corneal graft 
survival across a weak histocompatibility barrier.20 However, we have reported that the bilateral 
removal of some or all of the superficial cervical, facial, internal jugular and posterior cervical lymph 
nodes prior to corneal transplantation has no effect on the tempo or incidence of immunological 
rejection in the inbred WF/F344 combination.21 T cell sensitisation may occur within the eye, its 
environs, in other lymph nodes, or the spleen. Soluble antigen introduced into the rat anterior 
chamber has been tracked through the venous circulation into the cervical lymph nodes,22 but 
molecules of different molecular mass have been shown to partition differently after they leave the 
eye.23 Thus, whereas over 50% of 40 kDa dextran-Texas red appears subsequently in facial and 
cervical lymph nodes, smaller (5 kDa) and larger (500 kDa) dextran molecules cannot be detected in 
these nodes and may be taken up by terminal lymphatics, drain into the venous circulation,23 or be 
taken up by antigen-presenting cells in the anterior segment.24 The destination of our 28 kDa scFv, 
after it leaves the eye is unclear, but T cells in the loco-regional area or at a distance may be 
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targeted. We suggest the data support the contention that the anti-CD4 scFv is not affecting naïve 
CD4+ T cells in the cornea, but rather at a distance following drainage of the scFv from the aqueous. 
Alternatively, the scFv may be affecting CD4+ effector cells that take a little time to generate. 
In conclusion, our results indicate that lentivector-mediated, but not adenoviral vector-mediated, 
expression of anti-CD4 scFv from donor corneal endothelium is able to modulate allograft rejection, 
but the site of action of the transgenic protein is unknown. The fact that all of the corneal allografts 
did eventually reject indicates that sensitization and generation of an effector cell response did 
occur, but with delayed kinetics. Transfection of donor corneas ex vivo with both adenoviral and 
lentiviral vectors encoding a variety of transgenes has previously been shown to extend corneal 
allograft survival significantly.25 The decision as to which vector is best to use will depend upon the 
function of the transgenic protein being expressed: in some contexts, high levels of relatively short-
term expression may be warranted, whereas in others, sustained long-term gene expression may be 
necessary to achieve the desired effect. 
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Figure legends 
Figure 1: Anti-CD4 scFv expression from rat corneas transduced with LV-CD4scFv and Ad-CD4scFv. 
Rat corneas were transduced with Lv (MOI of 400) and Adv (MOI of 320) for 3h and cultured for 11 
days in a total volume of 2 ml. Culture supernatant was collected and replaced every 3 days from 
day 2. Flow cytometry on rat thymocytes using culture supernatants was performed to detect anti-
rat CD4 scFv via the his-6 tag. Error bars represent one standard deviation from the mean, n=3 
corneas. Comparisons were made between corneas transduced with Ad-CD4scFv and Lv-CD4scFv: 
****p<0.0001; ***p=0.0006; **p=0.004; *p=0.02 (unpaired two-tailed Student t-test).  
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